Cirrhosis/Liver Failure News

In a Healio video exclusive, Edward V. Loftus Jr., MD, urged gastroenterologists to familiarize themselves with a “four-pronged approach to liver disease” ahead of the critical shortage of U.S. hepatologists expected by 2033.

Physicians treating older veterans with dementia “should consider underlying cirrhosis” and use Fibrosis-4 as a screening tool to uncover reversible factors, such as hepatic encephalopathy, that may be associated with cognitive decline.

A $37 million study led by Newcastle University, University of Edinburgh and Boehringer Ingelheim is underway to address the “urgent need” for anti-scarring therapies for individuals with liver disease.

Use of nonselective beta-blockers was associated with stage 2 acute kidney injury and all-cause mortality among patients with decompensated cirrhosis waitlisted for liver transplantation, data showed.

Each January, Alcohol Change UK runs Dry January, a post-holiday campaign that encourages people to abstain from alcohol for 31 days at the beginning of the year and drink more healthily year-round.

Older adult patients with acute-on-chronic liver failure had significantly higher waitlist mortality but “acceptable” 1-year survival after liver transplantation, according to data in Clinical Gastroenterology and Hepatology.

Patients with cirrhosis are less frequently screened for osteoporosis compared with the general population, and less than 25% with low bone density actually receive treatment, according to research in Alimentary Pharmacology & Therapeutics.

In this Healio video exclusive, Dean Hum, PhD, chief scientific officer at Genfit, outlines five ongoing programs in the company’s acute-on-chronic liver failure development pipeline, which recently were presented at The Liver Meeting.

A new clinical guideline published in the American Journal of Gastroenterology underscored the need to overcome barriers to alcohol use disorder treatment and expand multidisciplinary care for patients with alcohol-associated liver disease.

The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor agonist-antagonist peptide for the treatment of ascites resulting from all causes except cancer, according to a company release.